2nd February 2022

pharmasol completes merger with PharmaLex Group

Strategic consolidation brings pharmasol’s industry-leading SUSAR distribution platform plus full-service pharmacovigilance business support capabilities to expanded Group

Kaiserslautern, Germany, February 2nd 2022 – pharmasol, a leading provider of specialist software and full-service solutions to optimise business-critical pharmacovigilance processes, today announces that it has completed a merger with PharmaLex – one of the world’s largest providers of specialised services for the pharma, biotech and medtech industries.

pharmasol brings key pharmacovigilance and end-to-end business support expertise to the expanded Group, extending the solution footprint of PharmaLex’s established Technology-Enabled Smart Services (TESS) division. With more than 20 years’ heritage in successfully serving the life sciences industry, pharmasol enables organisations to effectively implement, automate and optimise regulatory responsibilities, including SUSAR (Suspected Unexpected Serious Adverse Reactions) distribution via its industry-leading psiXchange platform. psiXchange is the only software developed exclusively for the business-critical process of automated safety letter distribution, today delivering state-of-the-art distribution capabilities to a diverse customer base spanning leading pharmaceutical and biotech companies and top 10 global CROs.

pharmasol’s full-service portfolio includes innovative applications, specialist consultancy, GxP compliant hosting and gold-standard implementation services – including rapidLIVE, an accelerated, pre-packaged and high ROI implementation solution for Oracle Argus Safety. 

“This strategic partnership with PharmaLex is a key milestone in our mission to create a dominant market position and enhance our total solution portfolio offering to our clients,” said pharmasol CEO Torsten Adam. “This landmark alliance empowers both organisations to offer greater depth and breadth of service in the fast-growing and highly competitive area of pharmacovigilance – from best-in-class IT solutions, hosting and business process automation to strategic consultancy services.”

“We are delighted to have completed this strategic merger with pharmasol, and to be enhancing our solution set with pharmasol’s proven, specialist solutions that support companies to cost-effectively and efficiently meet their regulatory and operational responsibilities while increasing compliance,” said PharmaLex CEO Dr. Thomas Dobmeyer. “With this consolidation of expertise from two industry leaders, we are excited to be further expanding our capabilities, and providing customers with access to pharmasol’s unparalleled technical expertise, highly talented team, and scalable, next-generation technology that will be instrumental in helping the industry to meet the complex data strategy and governance challenges, now and in the future.”

—Ends—

About PharmaLex

PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.

The PharmaLex Group now has over 1,700 employees, with 45 offices in 24 countries and more than 1,000 satisfied clients worldwide.

About pharmasol (https://pharmasol.de/)

pharmasol is a leading provider of specialist software and full-service solutions that optimise business-critical pharmacovigilance processes for the life sciences industry. pharmasol’s full-service portfolio includes innovative software applications, specialist sector consultancy, GxP compliant hosting and gold-standard implementation services, including Argus rapidLIVE, to help companies efficiently meet their regulatory and operational responsibilities – substantially reducing costs, boosting efficiency and increasing compliance for pharmaceutical, biotech and Clinical Research Organisations worldwide.

With more than 20 years’ heritage in delivering industry-leading solutions to life sciences organisations of all sizes, pharmasol enables organisations to effectively implement, automate and optimise key regulatory responsibilities across the entire pharmacovigilance function – including SUSAR document distribution via its industry-leading psiXchange platform.

For further information about pharmasol, please visit: www.pharmasol.de

psiXchange is the only software developed exclusively for the business-critical process of automated safety letter distribution, today delivering state-of-the-art capabilities to customers spanning leading pharmaceutical and biotech companies and top 10 global CROs. psiXchange provides a fully automated, best-in-class solution that streamlines complex, multi-site distribution processes for SUSARs, training materials and other critical safety documents – providing full tracking and audit capabilities and delivering improved compliance, greater oversight and significant cost savings. Global offices for pharmasol are located in Germany, the UK and the U.S.

PRESS CONTACT for Pharmasol:
Nicky Denovan
EvokedSet PR
Email: nicky[at]evokedset[dot]com
Phone: +44 (0) 118 328 2782

PRESS CONTACT for PharmaLex
Ms. Elizabeth Hunt
Manager External Communications
Email: elizabeth.hunt[at]pharmalex[dot]com
Phone: +00 353 86 811 2319